A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)
Eligible for screening study DCP 001
A052101 is temporarily closed to accrual to the optional Patient Assessment Life Survey (PALS) through the Patient Engagement Portal (PEP), effective October 1, 2025. Patients who elect to enroll in PALS during the temporary closure of PEP should complete Paper Booklet Questionnaire.
